RBM18

Across TCGA pan-cancer cohorts, RBM18 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RBM18 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RBM18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM18 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

UCEC, LUAD, and HNSC are the cancer types where RBM18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.542	1.000	.042	4	view →
LUAD	DFS	Median	III,IV	0.265	1.000	.038	3	view →
HNSC	OS	Tertile	All	1.000	0.924	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RBM18–UCEC (DFS)

Open the UCEC breakdown →